• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TRIFLUOPERAZINE Drug Record

  • Summary
  • Interactions
  • Claims
  • TRIFLUOPERAZINE chembl:CHEMBL422 Approved

    Alternate Names:

    STELAZINE
    STELAZINE FTE
    AMYLOZINE
    TRIFLUOPERAZINE
    ESKAZINYL®
    10-[3-(4-METHYL-1-PIPERAZINYL)PROPYL]-2-(TRIFLUOROMETHYL)-10H-PHENOTHIAZINE
    STELAZINE®
    TRIFLUPERAZINE
    TRIFLUOPERAZINA
    TRIFLUOROMETHYL-10-(3'-(1-METHYL-4-PIPERAZINYL)PROPYL)PHENOTHIAZINE
    10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE
    TRIFLUOROPERAZINE
    TRIFLUOPERAZINE HYDROCHLORIDE
    TRIFLUOPERAZINUM
    pubchem.compound:5566
    chemidplus:117-89-5
    rxcui:10800
    chembl:CHEMBL422
    drugbank:00831

    Drug Info:

    Drug Class antipsychotic agents
    Year of Approval 1959
    Drug Class antiemetics
    FDA Approval 1959
    Drug Class small molecule
    Drug Indications Antipsychotic Agents
    Drug Indications Antiemetics
    (3 More Sources)

    Publications:

    Fan et al., 2005, G protein-coupled receptor activation rapidly stimulates focal adhesion kinase phosphorylation at Ser-843. Mediation by Ca2+, calmodulin, and Ca2+/calmodulin-dependent kinase II., J. Biol. Chem.
    Seeman et al., 1976, Antipsychotic drug doses and neuroleptic/dopamine receptors., Nature
    Madrid et al., 2007, Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors., Bioorg. Med. Chem. Lett.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Sullivan et al., Augmentation of apoptosis by the combination of bleomycin with trifluoperazine in the presence of mutant p53., J. Exp. Ther. Oncol.
    Tay JK et al., 2007, Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia., Prog Neuropsychopharmacol Biol Psychiatry
    Lahti et al., 1993, Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications., Eur. J. Pharmacol.
    Schmidt et al., 1991, Investigation of striatal dopamine D2 receptor acquisition following prenatal neuroleptic exposure., Psychiatry Res
    Seeman, 2002, Atypical antipsychotics: mechanism of action., Can J Psychiatry
    Cahir et al., 2005, Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat., Eur Neuropsychopharmacol
    Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology
    Kastrinsky DB et al., 2015, Reengineered tricyclic anti-cancer agents., Bioorg Med Chem
    Mohindroo et al., 1997, Effect of trifluoperazine on certain arterial wall lipid-metabolizing enzymes inducing atherosclerosis in rhesus monkeys., Lipids
    Huerta-Bahena et al., 1983, Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects., Mol. Pharmacol.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Fujinaga et al., 1994, Receptor subtype and intracellular signal transduction pathway associated with situs inversus induced by alpha 1 adrenergic stimulation in rat embryos., Dev. Biol.
    Field et al., 1995, Esterification of plasma membrane cholesterol and triacylglycerol-rich lipoprotein secretion in CaCo-2 cells: possible role of p-glycoprotein., J. Lipid Res.
    Katayama et al., 1990, A role for calmodulin in the growth of human hematopoietic progenitor cells., Blood
  • TRIFLUOPERAZINE   CALY

    Interaction Score: 6.44

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    945467 17407813 11752352


    Sources:
    TdgClinicalTrial TEND

  • TRIFLUOPERAZINE   LIPA

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9270979


    Sources:
    NCI

  • TRIFLUOPERAZINE   EPM2A

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27092952


    Sources:
    PharmGKB

  • TRIFLUOPERAZINE   APOB

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7595077


    Sources:
    NCI

  • TRIFLUOPERAZINE   CAMK2B

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15845548


    Sources:
    NCI

  • TRIFLUOPERAZINE   ADRA1A

    Interaction Score: 0.18

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    6135146 17016423 17139284 8150214


    Sources:
    TdgClinicalTrial TEND

  • TRIFLUOPERAZINE   CSF2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1690578


    Sources:
    NCI

  • TRIFLUOPERAZINE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    8102973 945467 1676523 11873706 15695070 11752352


    Sources:
    TdgClinicalTrial TEND

  • TRIFLUOPERAZINE   AKT1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26372073


    Sources:
    DTC

  • TRIFLUOPERAZINE   THPO

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIFLUOPERAZINE   RAD52

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIFLUOPERAZINE   RGS4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIFLUOPERAZINE   TP53

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12415616


    Sources:
    DTC NCI

  • TRIFLUOPERAZINE   GLP1R

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIFLUOPERAZINE   DRD1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIFLUOPERAZINE   MAPK1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIFLUOPERAZINE   CBX1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIFLUOPERAZINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17611010


    Sources:
    DTC PharmGKB

  • TRIFLUOPERAZINE   USP1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIFLUOPERAZINE   ATXN2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIFLUOPERAZINE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIFLUOPERAZINE   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIFLUOPERAZINE   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIFLUOPERAZINE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: TRIFLUOPERAZINE

    • Version: 01-August-2011

    Alternate Names:
    TRIFLUOPERAZINE Primary Drug Name

    Drug Info:
    Drug Class antiemetics
    Year of Approval 1959
    Drug Class antipsychotic agents

    Publications:

  • TdgClinicalTrial: TRIFLUOPERAZINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antiemetics
    Drug Indications Antipsychotic Agents
    Drug Class small molecule

    Publications:

  • DTC: TRIFLUOPERAZINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL422 ChEMBL Drug ID

    Drug Info:

    Publications:
    Kastrinsky DB et al., 2015, Reengineered tricyclic anti-cancer agents., Bioorg Med Chem

  • NCI: TRIFLUOPERAZINE

    • Version: 14-September-2017

    Alternate Names:
    C904 NCI drug code

    Drug Info:

    Publications:
    Mohindroo et al., 1997, Effect of trifluoperazine on certain arterial wall lipid-metabolizing enzymes inducing atherosclerosis in rhesus monkeys., Lipids
    Katayama et al., 1990, A role for calmodulin in the growth of human hematopoietic progenitor cells., Blood
    Fan et al., 2005, G protein-coupled receptor activation rapidly stimulates focal adhesion kinase phosphorylation at Ser-843. Mediation by Ca2+, calmodulin, and Ca2+/calmodulin-dependent kinase II., J. Biol. Chem.

  • PharmGKB: trifluoperazine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tay JK et al., 2007, Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia., Prog Neuropsychopharmacol Biol Psychiatry
    Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology

  • TTD: Trifluoperazine

    • Version: 2020.06.01

    Alternate Names:
    D0R4OM TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL422

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21